Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more 2019 The Lancet Oncology 1593 citations